tiprankstipranks
Advertisement
Advertisement

SNGX Stock Latest News

Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy
Company AnnouncementsSoligenix Halts HyBryte Program, Refocuses Pipeline Strategy
20h ago
8K
SNGX
BARDA supporting development of Bundibugyo ebolavirus vaccine candidates
PremiumThe Fly
BARDA supporting development of Bundibugyo ebolavirus vaccine candidates
24h ago
GOVX
MRNA
Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine
PremiumThe Fly
Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine
5d ago
SNGX
Soligenix Expands At-The-Market Equity Financing Capacity
PremiumCompany Announcements
Soligenix Expands At-The-Market Equity Financing Capacity
16d ago
8K
SNGX
Soligenix reports Q1 EPS (28c) vs. (97c) last year
PremiumThe Fly
Soligenix reports Q1 EPS (28c) vs. (97c) last year
1M ago
SNGX
Soligenix price target lowered to $1.50 from $10 at Alliance Global
PremiumThe FlySoligenix price target lowered to $1.50 from $10 at Alliance Global
1M ago
SNGX
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
Premium
The Fly
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
2M ago
SNGX
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
Premium
Company Announcements
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
2M ago
8K
SNGX
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
2M ago
SNGX
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
PremiumThe FlySoligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
2M ago
SNGX
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
2M ago
SNGX
SNGX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
SNGX Earnings this Week: How Will it Perform?
3M ago
SNGX
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
3M ago
SNGX
Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
PremiumThe Fly
Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
3M ago
SNGX
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
3M ago
SNGX
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
3M ago
SNGX
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
PremiumTipRanks NewswireSoligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
3M ago
SNGX
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
3M ago
SNGX
Soligenix announces HyBryte clinical summary published
Premium
The Fly
Soligenix announces HyBryte clinical summary published
3M ago
SNGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >